Table 3

 Prevalence of BARD1 Cys557Ser among patients with familial breast or ovarian cancer, according to family history

Subgroup and study population*FrequencyOR (95% CI)p Value
ND, not determined due to lack of controls.
*Includes only samples for which the particular classification is known.
†Partly included in Karppinen et al.11
‡Norway not included.
§Altogether 10 patients had a family history of only ovarian cancer (two from Denmark, five from Sweden and three from Finland), and none of them carried BARD1 Cys557Ser mutation.
BRCA1/BRCA2 mutation-positive families
    Finland†0.0% (0/10)0.0 (0.0 to 24.06)0.68
    Iceland3.8% (2/53)1.2 (0.28 to 5.25)0.68
    Denmark1.6% (1/63)0.2 (0.03 to 1.61)0.15
    Sweden2.1% (2/97)0.5 (0.12 to 2.51)0.74
    Norway0.0% (0/27)NDND
    Total‡2.2% (5/223)0.8 (0.33 to 2.03)0.66
BRCA1/BRCA2 mutation-negative families
    Finland†6.0% (7/116)3.9 (1.70 to 9.11)0.005
    Iceland6.7% (7/104)2.2 (0.96 to 5.26)0.08
    Denmark5.8% (9/156)0.8 (0.37 to 1.78)0.60
    Sweden10.1% (8/79)2.9 (1.14 to 7.55)0.04
    Norway5.8% (8/138)NDND
    Total‡6.8% (31/455)2.6 (1.72 to 3.95)<0.001
Family history of breast cancer (without ovarian cancer)
    Finland†7.4% (7/94)4.9 (2.12 to 11.5)0.001
    Iceland6.7% (5/75)2.2 (0.83 to 5.92)0.10
    Denmark6.0% (7/117)0.8 (0.36 to 2.00)0.70
    Sweden7.3% (8/110)2.0 (0.80 to 5.21)0.13
    Norway4.1% (4/98)NDND
    Total‡6.8% (27/396)2.6 (1.68 to 4.05)<0.001
Family history of breast and ovarian cancer or only ovarian cancer§
    Finland†0.0% (0/32)0.0 (0.0 to 7.42)0.47
    Iceland9.1% (2/22)3.1 (0.70 to 13.9)0.16
    Denmark5.1% (2/39)0.7 (0.16 to 3.14)1.00
    Sweden3.0% (2/66)0.8 (0.18 to 3.76)1.00
    Norway5.7% (3/53)NDND
    Total‡3.8% (6/159)1.4 (0.60 to 3.24)0.45